BioInvent International AB BINV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BINV is a good fit for your portfolio.
News
-
BioInvent to Present Clinical Data from its Two Leading Assets at ASCO 2024
-
BioInvent International AB: Interim Report January-March 2024
-
BioInvent International AB Publishes Annual Report 2023
-
BioInvent Announces a New Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BI-1910, the Company’s Second Anti-TNFR2 Antibody in Combination with KEYTRUDA(R) (Pembrolizumab)
-
Notice to Annual General Meeting in BioInvent International AB
-
BioInvent International AB Year-end Report January 1 - December 31, 2023
-
Invitation to Presentation of BioInvent’s Year-end Report 2023
-
BioInvent to Evaluate BI-1206 in Combination with Rituximab and Calquence
Trading Information
- Previous Close Price
- SEK 23.20
- Day Range
- SEK 23.20–25.25
- 52-Week Range
- SEK 14.00–29.90
- Bid/Ask
- SEK 24.40 / SEK 24.50
- Market Cap
- SEK 1.63 Bil
- Volume/Avg
- 175,232 / 68,501
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 24.97
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's own clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin’s lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 112
- Website
- https://www.bioinvent.com
Comparables
Valuation
|
Metric
|
BINV
|
FUSN
|
IGMS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.24 | 7.64 | 2.30 |
Price/Sales | 24.97 | 676.42 | 195.50 |
Price/Cash Flow | — | — | — |
Price/Earnings
BINV
FUSN
IGMS
Financial Strength
|
Metric
|
BINV
|
FUSN
|
IGMS
|
|---|---|---|---|
Quick Ratio | 13.34 | 14.66 | 7.95 |
Current Ratio | 13.45 | 15.01 | 8.18 |
Interest Coverage | — | −19.06 | — |
Quick Ratio
BINV
FUSN
IGMS
Profitability
|
Metric
|
BINV
|
FUSN
|
IGMS
|
|---|---|---|---|
Return on Assets (Normalized) | −22.22% | −33.14% | −44.52% |
Return on Equity (Normalized) | −23.74% | −43.87% | −84.37% |
Return on Invested Capital (Normalized) | −23.36% | −36.42% | −77.23% |
Return on Assets
BINV
FUSN
IGMS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wkshhskjg | Fkcj | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vqrxvwdby | Yrrwj | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bxqrzjbb | Yrfwnkz | $99.5 Bil | |
MRNA
| Moderna Inc | Bqhxstcf | Nnsr | $38.8 Bil | |
ARGX
| argenx SE ADR | Zgvqrxfbd | Tlrk | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Fqrtnpztw | Ktlb | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wntnymxs | Wglzyrv | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Scdzdzznq | Jbfbhr | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mcgbnptnl | Bvhwlky | $12.5 Bil | |
INCY
| Incyte Corp | Hwlzsqs | Jykwt | $11.6 Bil |